Longevity Science Podcast

Certainty can be a red flag. I value intellectual honesty and admitting when you're wrong. Embrace new data and adjust your position. @mkaeberlein on The Aging Well Podcast youtube.com/watch?v=gvis-O…

BPC-157 shows potential for regeneration and wound healing in preclinical studies, but human data is scarce. #Science #Health #Research

Physicians need to understand safety data limitations. We need more clinical trials for promising peptides, not just anecdotes. Let's fund trials to know who benefits and the long-term risks. Just do the damn clinical trials! youtube.com/watch?v=lSidog…

Old mice fed a 3HAA-enriched diet showed extended lifespans. Starting the diet earlier (18-20 months) also resulted in lifespan extension. youtube.com/watch?v=BU98ev…

Worms with a unique red phenotype weren't just striking—they were building up high concentrations of 3HAA, a molecule linked to their remarkable longevity. A surprising insight into survival. #Science #Biology

Nice article in @nytimes by @SmithDanaG on the recent findings that circulating NAD levels do not decline with age in humans. nytimes.com/2026/05/23/wel… These new data are important because the original model was always supported more by marketing narratives and extrapolation than by strong human evidence. For years, the claim that “NAD declines with age” has often been presented as established fact when, in reality, the data were limited and inconsistent. To be clear, NAD biology absolutely matters. Understanding how NAD metabolism changes across specific tissues, disease states, and metabolic conditions remains an important scientific question. But absent convincing evidence that NAD broadly declines across tissues and organs during normal human aging, we should be willing to conclude that the broader hypothesis has failed. That’s how science is supposed to work. The burden of proof rests on those making the claims. The case for widespread NAD precursor supplementation as a gerotherapeutic is further weakened by the fact that preclinical studies reporting benefits for lifespan and healthspan have often lacked robust reproducibility across laboratories and model systems. And in humans, there is still remarkably little evidence supporting broad NAD precursor supplementation for otherwise healthy people. At the same time, I do think there are likely subsets of individuals with significant mitochondrial or metabolic dysfunction where NAD dyshomeostasis is real and therapeutically relevant. Those individuals may ultimately benefit from targeted interventions aimed at NAD metabolism. But the evidence increasingly suggests this is probably a small subset of people — not the average healthy aging adult. Science advances by testing hypotheses against data, not by repeating narratives until they become accepted dogma.

A clinical trial on rapamycin's effect on exercise response in older adults (65-85) yielded surprising results. Despite improvements in both groups, the rapamycin group showed less improvement than the placebo group after 13 weeks. What does it mean? #Longevity #Health #Science

Borderline thyroid dysfunction is increasingly common. Doctors are now prescribing T4 and T3 for those with slightly elevated TSH and low free T3, especially when symptoms are present. This condition may be underdiagnosed. #ThyroidHealth #Endocrinology

Lineage 2 is the top health tracker because it's actionable. It tells you exactly what to do to improve biomarkers and reduce mortality, as predicted by its algorithm. #HealthTech #Longevity

Resilience changes as we age. As you get older, you're more likely to reach a tipping point where your ability to bounce back shifts. #Resilience #AgingWell

The biggest danger isn't injecting peptides, it's the impurities and manufacturing flaws in the source. Always be aware of what you're injecting. #PeptideSafety #Health

GLP-1 agonists are altering personalities by dampening cravings for smoking, drinking, and even addictive behaviors like gambling. If a peptide can change who someone is, what does that say about more fundamental influences on our personality? #Science #Behavior #Addiction

Berberine vs. Metformin: Both molecules may do the same thing, but one is OTC while the other is prescription. Pharmaceuticals aren't inherently different from supplements—they're just regulated differently.

Really excited to share a new episode of @longevityscipod : “Longevity Roundtable: Rapamycin, Reprogramming, Peptides & Proactive Healthcare” youtube.com/watch?v=lSidog… I sat down with @BKennedy_aging and @docmranney for a wide-ranging conversation on some of the biggest questions in longevity science right now. We discussed: Why “proactive healthcare” unexpectedly won Longevity March Madness Whether FDA-approved drugs should be used proactively before disease develops The ethics and risks of experimental peptides and off-label therapeutics What we should actually conclude from @BradStanfieldMD's rapamycin trial Why peptide science is simultaneously promising and dangerously under-regulated The first human epigenetic reprogramming trials and what they may mean for the future Whether reprogramming could someday alter not just aging biology, but aspects of personality and behavior One of the themes that emerged repeatedly is that longevity medicine is still in an awkward but fascinating transition period: enormous enthusiasm, incomplete evidence, real biological promise, and a desperate need for better clinical trials and better data. I appreciated how nuanced and intellectually honest this conversation was. We agreed on some things, disagreed on others, and tried to stay grounded in what the science actually supports versus what people hope is true. At the end of the day, all three of us came back to the same core principle: The fundamentals still matter most — sleep, movement, nutrition, metabolic health, relationships, and proactive care long before disease appears. Would love to hear your thoughts after you watch it. What do you think is currently the most promising — and most overhyped — area in longevity science?

DNP served as a cautionary tale for experimental drugs. It didn't fail because it didn't work, but because its users and prescribers didn't understand the biology, leading to preventable deaths. A lesson in caution. #MedicalEthics #DrugSafety

I’m thrilled to announce my new podcast, Longevity Science with Matt Kaeberlein. Episode 1 is now live and takes a deep dive into the story of dinitrophenol (DNP) — an experimental weight loss drug linked to hundreds of deaths and a cautionary reminder of what can happen when enthusiasm for new therapies gets ahead of the science. Episode 2 drops Friday and features a Longevity Roundtable with @BKennedy_aging and @docmranney . We discuss proactive healthcare, rapamycin, peptides, epigenetic reprogramming, biological age testing, and where the field of longevity medicine may be headed next. My goal with this channel is simple: thoughtful, evidence-based conversations that separate signal from noise in the rapidly evolving world of longevity science. I hope you’ll check it out — and subscribe on YouTube, Spotify, or wherever you listen to podcasts. YouTube: @mkaeberlein" target="_blank" rel="nofollow noopener">youtube.com/@mkaeberlein Spotify: open.spotify.com/show/7DRRH5lfL…

Some functional medicine doctors are prescribing a drug with essentially zero human safety data. The drug is called SLU-PP-332. It’s being marketed in some circles as a “mitochondrial activator” or exercise mimetic. Here’s the problem: as far as I can tell, there are no human clinical trials showing safety or efficacy. Just a handful of mouse studies. And these aren’t patients with life-threatening disease and no options. These are relatively healthy men and women wanting to lose weight. That honestly shocked me. Because we’ve seen this story before. In the 1930s, another so-called metabolic activator called DNP became extremely popular before researchers fully understood the risks. That drug ultimately caused cataracts, hyperthermia, and hundreds of deaths. Absence of safety data does not mean something is safe. That’s a lesson the longevity field really needs to remember. Check out the full-length video: youtube.com/watch?v=C3Ca8e…